Syed A Hussain

Professor of Medical Oncology Department of Oncology and Metabolism Medical School, Beech Hill Road, Sheffield

[Syed A Hussain @ProfSyedHussain]

Great to see you growing, Saad. Your hard work and determination have been the key to your success, and I'm sure you'll make the most of this exciting opportunity.
Keep your feet on the ground, stay focused, and continue working hard;the sky's the limit. I am very proud of you.

[Saad Nasir, MD @saadnasir01]

Excited and grateful to begin my fellowship at MD Anderson Cancer Center.

Looking forward to learning, growing, and serving patients. Thankful to everyone who has helped me reach this point.

[Syed A Hussain @ProfSyedHussain]

It was a pleasure to see you and colleagues from Malaysia and Singapore during the ASCOMOS and MSCM as well. Had great discussions. Thanks for the hospitality. @teng_ong @Marnizasaad @ravikanesvaran @ChinchuanOoi #esmo #esmoasai @myESMO @ASCO

[Ong TA @teng_ong]

Exploring the details of the practice changing NIAGARA trial for bladder cancer with @ProfSyedHussain in Kuala Lumpur.

[Syed A Hussain @ProfSyedHussain]

@Marnizasaad @teng_ong @ChinchuanOoi

[Syed A Hussain @ProfSyedHussain]

It was a pleasure to see you and colleagues from Malaysia and Singapore during the ASCOMOS and MSCM as well. Had great discussions. Thanks for the hospitality. @teng_ong @Marnizasaad @ravikanesvaran @ChinchuanOoi #esmo #esmoasai @myESMO @ASCO

[Syed A Hussain @ProfSyedHussain]

It was my great pleasure to be part of SMOP urology masterclass. Delighted 2 see the enthusiasm&commitment of the next generation of trainees &consultants. Thanks for the kind invitation & the hospitality; Narjis Muzaffar, Najeeb Niamatullah ,Adnan Jabbar,Zeba Aziz. @SMOP #SMOP

[Syed A Hussain @ProfSyedHussain]

Gr8 2 c that Nick.Delighted 2 be coauthor. From Phase 1 to phase III bc2001 2Tuxedo trial & now RADio together, gr8 Journey @JimCatto @tompowles1 @scserendipity1 @CRFSheffield @sheffielduni @TUOS_Cancer @Shef_Research @yorkshirecancer @WPCancerCharity @Prof_Nick_James @DrChoueiri

[Nick James @Prof_Nick_James]

Nice piece of coverage for our RADIO data presented at #asco26 https://t.co/OK6VMt4Mvj

[Syed A Hussain @ProfSyedHussain]

Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery | Cancer research | The Guardian. Great to see our RADio trial highlighted by guardian. Study investigated addition of Durvalumab to concurrent chemo RT. @prof_nick_james https://t.co/ogy0kkFWqT

[Syed A Hussain @ProfSyedHussain]

It was a pleasure to see you and catch up @drnawazniazi1 @saadnasir01 . Keep in touch.

[Dr. Muhammad Nawaz Khan Niazi @drnawazniazi1]

Delighted to have an Inspiring and insightful discussion with @Prof_Nick_James @ProfSyedHussain @saadnasir01 at the ASCO2026.

[Urologic Oncology @UrolOncol]

🔥@UrolOncol June issue!

Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis by @YuGuangTan1 and @UroDocAsh et al

🔗https://t.co/nAXeHcpdm6

[Syed A Hussain @ProfSyedHussain]

ASCO 2026 brought exciting data that will improve outcome for pts globally. Our MIBC organ preservation trial was presented by Nick.I presented cis v Carbo data from DISCUS trial. We saw amazing and exciting data across cancers.Thank you @asco committees for a stimulating meeting

[Syed A Hussain @ProfSyedHussain]

Many thanks @Xesiloglu . It was my pleasure to catch up and discuss future research ideas. @DrYukselUrun @DenizCanGuven1 @CliffordHudis @fumikochino @ASCO @ASCOPost

[Enes Yeşilbaş @Xesiloglu]

🎗️ ASCO26 Day 3

🎤 A day filled with inspiring plenary sessions and thought-provoking discussions at ASCO26.

🤝 It was a pleasure to meet Dr. @CliffordHudis, CEO of ASCO, and to connect with Dr. @fumikochino, whose work continues to highlight the importance of patient-centered outcomes in breast cancer care.

🌍 Meeting and exchanging ideas with outstanding colleagues such as @MGMcNamara and Dr. @ProfSyedHussain Hussain was equally rewarding and inspiring.

✨ From leadership and advocacy to innovation and collaboration, @ASCO continues to bring together the people shaping the future of cancer care.

🎗️ #ASCO26 #ASCO #IDEA2026 #ConquerCancer #GlobalOncology #CancerResearch #OncologyCommunity

@kbaskurtt

[Syed A Hussain @ProfSyedHussain]

FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC - The ASCO Post https://t.co/EDQlPeN50g

[Syed A Hussain @ProfSyedHussain]

This is exciting news. VOLGA provides more options for our patients with MIBC. QOL and details about efficacy and toxicity differences will be key. Thanks to patients who took part and their families for the support. Gr8 work & well done to the global GU colleagues. @tompowles1

[Tom Powles @tompowles1]

Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. Details of efficacy and toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage. https://t.co/p0iGvSDxs6 @OncoAlert

[Enrique Grande @drenriquegrande]

What great news!!!!! 👏👏👏👏👏👏👏
Perioperative Durvalumab plus EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial.
@OncoAlert @seom @CANVES_ES @GUOncologyNow @OncBrothers @myESMO

https://t.co/uOS52u6l7V

[Yüksel Ürün @DrYukselUrun]

VOLGA is positive: perioperative durvalumab + neoadjuvant EV improves EFS and OS in cisplatin-ineligible MIBC.
Key difference from KEYNOTE trials: no adjuvant ADC here, only IO. So in pCR patients, is adjuvant ADC really needed? Looking forward for details.
@OncoAlert @ONCOassist @Uromigos @tompowles1 @Larvol @MedwatchKate

[Syed A Hussain @ProfSyedHussain]

It was a pleasure and privilege to attend and present as faculty at the Avenues Meeting organised by Merck in Prague. More than 450 colleagues from 35 countries participated in this exciting and highly collaborative event. It was inspiring to learn from one another’s experiences.

[Félix Guerrero-Ramos @DrFelixGuerrero]

🇨🇿Less than 24 hours in beautiful Prague
🆒Really enjoyed speaking & discussing about #bladdercancer at #MedicalAvenues by @merckgroup
🫂Happy to meet great friends @drenriquegrande @ProfSyedHussain @AlisonBirtle

[Syed A Hussain @ProfSyedHussain]

Great to see you and catch up. @AlisonBirtle

[💙alison birtle @AlisonBirtle]

#bladdercancerawarenessmonth in #Prague for @merckgroup #avenues. @ProfSyedHussain

[Syed A Hussain @ProfSyedHussain]

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer https://t.co/CPxCPgZacr

[Enes Yeşilbaş @Xesiloglu]

🏆🏆 Proud to share that we completed the 13th Turkish Medical Oncology Congress with two awards as a team.

👍 Our PRO-HAND study received the Best Oral Presentation Award, led by my mentor Dr. Osman Sutcuoglu ( @osutcuoglu )

🙏 Grateful to Dr. Kadriye Başkurt (@kbaskurtt ), Dr. Tuba Uğur Tuzca ( @tubaugurdr ), and Dr. Orhun Akdoğan ( @drOrhunakdogan ) for their valuable contributions

👏 Special congratulations to Dr. Galip Can Uyar ( @uyargalip ) for the Best Paper Award

🎯 Thanks to the organizing committee, especially Dr. Deniz Can Güven ( @DenizCanGuven1 ), Dr. Şahin Laçin ( @DrSahinLacin ), and Dr. Mehmet Ali Nahit Şendur ( @nahit_sendur ), for an outstanding congress

🌍 It was a great pleasure to host distinguished experts such as Dr. Jonathan Lim ( @DrJonLim ), Dr. Benedikt Westphalen ( @BenWestphalen ) , Dr. Aung Naing ( @ANaingMD ), Prof. Andrés Cervantes ( @AndresC27622123 ), Prof. Christopher Sweeney ( @ChrisSweens1 ), Dr. Marco Tagliamento ( @M_Tagliamento ), Dr. Samer Srour , Prof. Tom Powles ( @tompowles1 ), and Prof. Syed Hussain ( @ProfSyedHussain )

🌐 We will continue working to strengthen the global visibility of our oncology community and represent our country at the highest scientific level🇹🇷

#Oncology #MedicalOncology #CancerResearch #TTOD #GlobalOncology #ASCO #ESMO